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Summary Epidemiological studies have revealed that consumption of milk and fermented dairy products is inversely
associated with elevated blood pressure and with many of the risk factors of the metabolic syndrome. Pre-
viously, calcium was thought to be behind this phenomenon, but during the last 20 years, convincing evi-
dence emerging from experimental, epidemiological and intervention studies has highlighted the important
role of the small peptides formed during fermentation processes. This review provides an overview of the
potential blood pressure lowering components present in dairy products with a special focus on casein-
derived tripeptides.
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Introduction
Hypertension is a major risk factor for the develop-
ment of stroke, heart failure, ischaemic heart and renal
diseases and is often associated with the metabolic syn-
drome. Drug treatment can be effective, but compli-
ance is poor for two important reasons: hypertension,
even if moderate, is often symptomless and the drugs
used to treat hypertension can cause unpleasant
adverse effects. Therefore, nutritional advice and treat-
ment, for example reductions in salt intake and alco-
hol consumption, in addition to physical exercise, are
beneficial. Epidemiological or prospective follow-up
studies (Engberink et al., 2009; for reviews see
McGrane et al., 2011; Raiston et al., 2012; Chrysant
& Chrysant, 2013; Buendia et al., 2018; Lee et al.,
2018) as well as short-term intervention studies (van
Meijl & Mensink, 2011) have demonstrated that the
consumption of dairy products, especially low-fat
products, is inversely associated with the blood pres-
sure level. Interestingly, although the systolic blood
pressure values of both groups of Caucasians increased
during the 9-year follow-up in the Atherosclerosis Risk
in Communities Study, it was found that the blood
pressure levels of those consuming three or more daily
servings of low-fat milk increased by 2.7 mmHg less
than of those consuming less than one weekly serving.
However, in African Americans, the intake of dairy
products was not associated with any changes in blood
pressure (Alonso et al., 2009). Furthermore, a meta-
analysis (Soedamah-Muthu et al., 2012) of prospective
cohort studies indicated that low-fat dairy and milk
could contribute to the prevention of hypertension.
Calcium has traditionally been regarded as being the
beneficial component present in dairy products. In
fact, its role in essential hypertension has been claimed
to be even more important than that of sodium
(McGarron, 1985). The role of electrolytes, for exam-
ple, the high levels of calcium, potassium and magne-
sium as well as the low amounts of sodium present in
milk products, has also been discussed (Massey, 2001).
During the last 25 years, some short peptides formed
in bacterial or enzymatic fermentation have attracted
more and more interest due to their angiotensin con-
verting enzyme type 1 (ACE1) inhibiting properties.
This review will mainly focus on these bioactive
tripeptides but it also examines briefly the possible role
of other compounds present in milk which, at least
theoretically, may beneficially influence blood pressure.
For the literature search we used PudMed, Ovid Med-
line and Scopus databases.
Milk-derived bioactive peptides
Due to its high protein content, milk is a good source
of potentially bioactive peptides. At present, bioactive
peptides are known to be formed from both the two
main proteins in milk: caseins (alpha-, beta- and
kappa-casein) and whey proteins, for example, alpha-
lactalbumin and beta-lactoglobulin. This review will
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focus only on antihypertensive peptides although dairy
products have been shown to contain peptides which
potentially could influence many other physiological
processes in addition to the cardiovascular system (see
Park & Nam, 2015; Korhonen & Pihlanto-Lepp€al€a,
2016; Mohanty et al., 2016).
ACE-inhibiting peptides
The antihypertensive effects of milk-derived peptides
are believed to be mainly attributable to the inhibition
of angiotensin converting enzyme type 1 (ACE1). In
fact, many ACE inhibitory peptides have been identi-
fied in dairy products from different source of milk,
such as cow (Mullally et al., 1997; Sieber et al., 2010;
Rodriguez-Figueroa et al., 2012), camel (Moslehishad
et al., 2013; Yahya et al., 2017), goat (Chen et al.,
2018) and mare (Chen et al., 2010). So far of three
tripeptides, isoleucine-proline-proline (Ile-Pro-Pro),
valine-proline-proline (Val-Pro-Pro) and leucine-pro-
line-proline (Leu-Pro-Pro), have been the most exten-
sively evaluated (Nakamura et al., 1995; Masuda
et al., 1996). ACE1 is the key enzyme in the renin-
angiotensin system (RAS), and its inhibition reduces
the level of one of the body’s most potent vasocon-
strictors, angiotensin II, thus ACE1 inhibition is able
to reduce the blood pressure. The first orally active
ACE-inhibiting medicine, captopril, was approved by
the FDA in 1981.
Bioactive peptides can be formed in three different
ways from milk proteins: (i) during the fermentation
process by certain lactic acid bacteria or yeasts, (ii)
during food processing by enzymatic hydrolysis and
(iii) by gastrointestinal enzymes. Food processes can
be controlled to ensure that they produce and even
enrich certain peptides but the third route is a sponta-
neous physiological process that cannot be controlled.
Lee et al. (2007) tested the effects of consumption of
a milk drink supplemented with whey peptides in
mildly hypertensive subjects. The 12-week trial did not
find evidence of any blood pressure reduction as com-
pared to controls, although whey peptides had earlier
been shown to have ACE inhibitory activity in vitro
(Mullally et al., 1997; FitzGerald & Meisel, 1999).
Chobert et al. (2005) tested the ACE inhibitory activ-
ity of the whey protein, b-lactoglobulin from ovine
milk, after its digestion with trypsin. They revealed
that the hydrophilic, smaller peptides were more
potent ACE inhibitors than beta-lactoglobulin itself,
although the fragments they tested contained several
different peptides.
In the study by Ashar & Chand (2004) fermented
Dahi milk enriched with peptide Ser-Lys-Val-Tyr-Pro
was fed for 8 weeks to hypertensive subjects from
three different age groups: under 45, 45–55 and over
55 years old. The authors conclude that blood pressure
was decreased in the middle-aged group (45–55 years
old) when compared to placebo group. Also, serum
cholesterol levels decreased in all the subjects consum-
ing fermented milk product.
ACE-inhibiting peptides have been isolated from
various cheeses (Sieber et al., 2010). For instance,
Saito et al. (2000) tested the ACE inhibitory activity
of different cheeses and evaluated their antihyperten-
sive effects using animal models. The peptide content
of the most potent cheese, 8-month-old Gouda, was
investigated and pure peptides were isolated and exam-
ined. Two peptides – Arg-Pro-Lys-His-Pro-Ile-Lys-
His-Gln and Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn
from a- and b-casein displayed ACE inhibitory and
slight antihypertensive activity. Gomez-Ruiz et al.
(2006) identified peptide fragments different Spanish
cheeses. They examined the ACE inhibitory activity of
cheeses and chemically synthesised proline in the C-
terminal consisted peptides from cheese variates. All
tested peptides showed ACE inhibitory action, how-
ever, peptide Asp-Lys-Ile-His-Pro was the most potent.
The impact of probiotic bacteria on the content of
the bioactive peptides has been investigated during the
cheese ripening process. Ong et al. (2007) tested the
ACE inhibitory activity of Cheddar cheese when cer-
tain probiotic lactic acid bacteria were added during
the ripening process. They measured the ACE inhibi-
tory activity of the chromatographically separated
fractions of the cheese. The peptide content of the
most potent fractions was assayed and found to be
linked with an amino acid sequence present in different
caseins. Ryh€anen et al. (2001) investigated the ACE
inhibitory activity of cheese supplemented with probi-
otic bacteria and showed that the ripening time
affected the ACE inhibitory activity. The most potent
peptide sequence was obtained from as1-casein.
Ile-Pro-Pro, Val-Pro-Pro and Leu-Pro-Pro
When milk is fermented with Lactobacillus helveticus,
or with common yeast Saccharomyces cerevisiae, three
tripeptides, Ile-Pro-Pro, Val-Pro-Pro and Leu-Pro-Pro,
are released from beta-casein. It has been demon-
strated with different experimental hypertension mod-
els that the administration of tripeptide-containing
products can lower elevated blood pressure (Table 1).
The main mechanism of action is believed to be the
inhibition of ACE. However, it seems that consump-
tion of these tripeptides affects also other blood pres-
sure lowering mechanisms such as NO bioavailability
(Hirota et al., 2011) and the angiotensin (1–7)-Mas-
receptor-axis (Siltari et al., 2016). ACE inhibition also
prevents the breakdown of bradykinin which may act
synergistically with the reduced formation of angioten-
sin II to lower the blood pressure by increasing arterial
vasodilatation (Siltari et al., 2017).
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Not only blood pressure is lowered by tripeptide
feeding but there are also improvements in the
endothelium-dependent vascular function (J€ak€al€a
et al., 2009a; Ehlers et al., 2011; Nonaka et al., 2014)
(Table 1). Furthermore, the endothelium-dependent
vascular relaxation persisted when mesenteric artery
rings from hypertensive animals were bathed in a buf-
fer containing Ile-Pro-Pro at +4C even after 24 h
(J€ak€al€a et al., 2009b). Hirota et al. (2011) showed that
Ile-Pro-Pro and Val-Pro-Pro could relax pre-con-
tracted isolated aorta rings of normotensive animals
and this dilatation could be abolished by removal of
the endothelium, by blocking nitric oxide formation or
by treatment with bradykinin type 2 receptors. Thus,
these tripeptides seem to induce the formation of nitric
oxide and other vasodilating compounds. Recently, it
was reported that there were increases in the plasma
bradykinin concentration of normotensive volunteers
after an acute intake of a high dose of the tripeptides
(Nussberger et al., 2018).
In clinical trials, tripeptide-containing dairy products
have lowered blood pressure of mildly/borderline
hypertensive humans (see Nongonierma & FitzGerald,
2015; Park & Nam, 2015; Korhonen & Pihlanto-
Lepp€al€a, 2016; Mohanty et al., 2016; Marcone et al.,
2017). Table 2 illustrates the main findings from all of
the meta-analyses from milk peptides conducted so
far. Turpeinen et al. (2013) analysed 19 clinical trials
with a total of over 1500 patients and concluded that
the overall antihypertensive effect of tripeptides was 4.0
mmHg in the systolic blood pressure (SBP) and 1.9
mmHg in the diastolic blood pressure (DBP). If the
analysis was restricted only to studies conducted in
Asian populations (Chanson-Rolle et al., 2015), then
the overall blood pressure lowering effect of tripeptide
consumption was even higher: 5.6 mmHg in SBP
and 2.6 mmHg in DBP. One meta-analysis restricted
to only the European studies (Cicero et al., 2013)
claimed that the blood pressure lowering effect was
slightly lower (1.3 mmHg in SBP and 0.6 mmHg
in DBP) than the values obtained in analyses involving
all the clinical studies.
The meta-analysis conducted by Qin et al. (2013)
reported similar results: 1.7 mmHg SBP and
0.8 mmHg DBP. However, their sub-analyses
revealed interesting findings that is that the blood pres-
sure lowering impact of tripeptides varied not only
between the Asian and European populations but also
between the study designs (single or double blinded),
baseline blood pressure level of subjects (pre-hyperten-
sive or hypertensive) and even the source of the pep-
tide (fermentation or enzymatic hydrolysis) was














compared to controls Notes
Nakamura et al. (1995) SHR 8 h 0.9 18 Not measured Single dose
Nakamura et al. (1996) SHR 16 dns 19 Not measured Diet contained sour
milk powder containing
tripeptides
Masuda et al. (1996) SHR 6 h 0.4 26 Not measured Single dose
Sipola et al. (2001) SHR 12 2.5–3.5 17 Not measured
Sipola et al. (2002) SHR 14 1  0.5 21 Not measured Daily dose/rat
Jauhiainen et al. (2005) SHR 9 1.5  0.1 17 No differences Daily dose/rat
Jauhiainen et al. (2010a,
2010b)
dTGR 3 4.1  1.1 19 Not measured
J€ak€al€a et al. (2009c) SHR 8 2.8–5.2 14 No differences
J€ak€al€a et al. (2009a) G-K + salt 8 4.6–6.6 12 Improved
J€ak€al€a et al. (2010) SHR 8 6.3–8.7 14 No differences
Kim et al. (2010) SHR 8 dns dns Not measured Orally administered
powder containing tripeptides
(0.6%) 10 mg kg1 daily
Ehlers et al. (2011) SHR 6 4.1  0.1 16 Improved Experimental drink which
contained plant sterols (daily
dose 1.9 g kg1)
Ehlers et al. (2012) SHR 8 4.2  0.1 18 No differences Experimental drink which
contained plant sterols (daily
dose 2 g kg1)
Siltari et al. (2017) SHR 6 4.7–5.1 20 No differences Daily dose/rat
dns, data not shown; dTGR, double transgenic rats harbouring human renin and human angiotensinogen genes; G-K + salt, salt loaded Goto-Kaki-
zaki rats; SBP, systolic blood pressure; SHR, spontaneously hypertensive rats.
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crucial. A fermentation process may produce also dif-
ferent bioactive peptides or compounds other than
those of interest. This means that products manufac-
tured by fermentation may have a greater impact due
to the fact that they may also contain some other, still
to be characterised, blood pressure lowering com-
pounds. Nevertheless, tripeptides originating from dif-
ferent production methods (enzymatic hydrolysis or
fermentation with Lactobacillus helveticus) were
roughly equally successful in lowering blood pressure
as compared to water consumption in hypertensive
rats (SHR) (J€ak€al€a et al., 2010).
It is not clear, why tripeptide consumption seems to
be more efficient in Asian populations but one can
speculate that lifestyle related factors, such as diet and
genetic factors may play a role. For instance, cheeses
contain tripeptides which are formed during the cheese
ripening process (Sieber et al., 2010). Cheeses have a
more important part in the daily diet in Europe than
in Asia. Thus, a European population is most likely
consuming dairy products and thus bioactive tripep-
tides already before clinical trials and will not benefit
so much from supplementation with some specific pep-
tide-enriched dairy product.
Four of the meta-analyses (Xu et al., 2008; Qin
et al., 2013; Chanson-Rolle et al., 2015; Fekete et al.,
2015) conducted sub-group analyses separately for pre-
hypertensive and hypertensive subjects. These analyses
revealed that tripeptide feeding lowered blood pressure
more efficiently in hypertensive subjects although the
reduction was statistically significant also in the pre-
hypertensive subjects. When recruiting mildly hyper-
tensive subjects to clinical trials, we noted that out of
the nearly 400 mildly hypertensive volunteers (BP as
measured by a nurse or physician >140/90 mmHg),
only 96 were clearly still hypertensive after the run-in
period when assessed by ambulatory 24 h monitoring
and ultimately only 89 were enrolled in the yogurt
intervention trial based on truly elevated blood pres-
sure (Jauhiainen et al., 2007). This possible pitfall in
study population recruitment has not been taken into
account in all of the clinical studies.
Based on both the clinical and experimental studies,
it does seem to be the case that tripeptide-containing
products need to be consumed daily for several weeks
before any significant blood pressure reduction can be
detected. This was seen also in a subgroup meta-
analysis where the analysis was performed based on
the duration of the peptide intake (less or more than
8 weeks): the antihypertensive effect of tripeptide
ingestion was greater after consumption for 8 weeks or
more (Qin et al., 2013). Interestingly, when the 8-
week-long treatment with a peptide containing fer-
mented milk was interrupted, the slightly reduced
blood pressure returned to the initial level during a 4-
week-long follow-up (Seppo et al., 2002).
It seems that tripeptide feeding decreases arterial stiff-
ness in humans when this is assessed with an augmenta-
tion index, AIx (Jauhiainen et al., 2010a, 2010b) even
without any changes in blood pressure. In the long run,
this effect may also decrease blood pressure; however,
with or without an effect on blood pressure, the reduced
arterial stiffness will decrease the risk of the develop-
ment of atherosclerosis and the risk of serious cardio-
vascular events such as stroke and cardiac infarcts.
Furthermore, in an in vitro model, Aihara et al. (2009)
showed that pre-incubation of monocytic cells with Val-
Pro-Pro decreased the adhesion of monocytes to human
endothelial cells. They also showed that Val-Pro-Pro
decreased the expression of integrins and reduced the
phosphorylation of c- Jun N-terminal kinase (JNK),
two important pathways in the adhesion of monocytes
to endothelium. The authors concluded that Val-Pro-
Pro might possess an anti-atherosclerotic potential in
conditions where there is low grade inflammation of the
endothelium, like in hypertension and aging.
Bioavailability of food-derived components, that is,
their absorption from intestine to the systemic circula-
tion is an important issue when examining the physio-
logical effects of nutrients. Ile-Pro-Pro, Leu-Pro-Pro
and Val-Pro-Pro have been detected in the circulation
after oral administration of dairy products enriched
with these peptides both in experimental and human
studies (Jauhiainen et al., 2007; van der Pijl et al., 2008;
Kawaguchi et al., 2012; Gleeson et al., 2017). The levels
of the detected tripeptides are low; however, but there
were some indications that there was an accumulation
of peptides in blood pressure regulating organs. Jauhi-
ainen et al. (2007) administered radio-labelled Ile-Pro-
Pro to spontaneously hypertensive rats (SHR) both
intravenously and orally and subsequently radioactivity
was detected in aorta, heart and kidneys for as long as
48 h after their administration. Kawaguchi et al. (2012)
detected labelled Ile-Pro-Pro and Val-Pro-Pro in the
endothelium of rats after oral administration of these
compounds. They also measured Ile-Pro-Pro and Val-
Pro-Pro concentrations in plasma and tissues; liver, kid-
neys, lung and aorta (concentrations from lowest to
highest). Foltz et al. (2007) conducted a trial in volun-
teers; it was found that Ile-Pro-Pro selectively escaped
intestinal breakdown and reached the circulation un-
degraded.
Proline-proline bond containing peptides has been
claimed to be resistant to digestion in the gastrointesti-
nal tract. The stability of Ile-Pro-Pro against intestinal
degradation was tested using rat intestinal rinses,
intestinal proteases and homogenates from intestine
and liver (Ohsawa et al., 2008; Gleeson et al., 2015).
Ile-Pro-Pro seemed to be rather stable in these in vitro
setups. Furthermore, Ile-Pro-Pro was not cytotoxic
even after chronic exposure to Hep G2 and caco-2
cells (Gleeson et al., 2015).
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The toxicity of tripeptide feeding has been evaluated
in an embryo-foetal development test in rabbits, in a
90-day repeated-dose oral gavage test in rats as well as
in a pre- and post-natal development test in rats (Dent
et al., 2007) with no serious adverse effects being
observed in any of these tests. Other toxicity studies
on tripeptide feeding have come to the same conclu-
sion (Beltran-Barrientos et al., 2017). Furthermore,
none of the clinical trials have reported any significant
adverse effects associated with tripeptide feeding, with
the adverse effects of the tripeptide consumption
being typical of dairy products such as abdominal
discomfort.
Antithrombotic peptides
Studies conducted already in the 1980s and 1990s
showed that peptides derived from lactoferrin (Fiat
et al., 1989; Qian et al., 1995) and caseins (Jolles et al.,
1986; Fiat et al., 1989) inhibited ADP-induced platelet
aggregation in vitro. Drouet et al. (1990) investigated
the effects of lactoferrin-derived peptides on platelet
aggregation in vitro as well as on arteriolar thrombosis
in vivo in rats and guinea pigs; it was noted that these
peptides inhibited both the aggregation of activated
platelets and prevented thrombosis. Furthermore, Bal
dit Sollier et al. (1996) showed that the antithrombotic
effect of caseinoglycopeptides was even more marked
in vivo than in vitro; in guinea pigs, the antithrombotic
effect was achieved in vivo with a lower concentration
than that preventing platelet aggregation in vitro. In
addition, the antithrombotic activity of whey proteins
has been investigated; j-casein macropeptide and its
tryptic hydrolysate have been reported to exert an
inhibitory activity against platelet aggregation (Manso
et al., 2002).
Peptides with opioid-like properties
Milk contains peptides with a natural opioid-like activ-
ity; however, these compounds can also be formed
in vitro during the fermentation process or cheese
ripening or they can be formed in vivo during gastroin-
testinal digestion (Nguyen et al., 2015). This review
examines only the possible cardiovascular effects of
opioid peptides, but it is clear that these compounds
have effects on many other physiological functions,
such as gastrointestinal motility, food intake, analgesia
and immunomodulation (see, Kostyra et al., 2004).
b-Casomorphines are components of b-casein. The
most widely studied compound in this family is b-caso-
morphine-7. The opioid-like peptides formed from
a-casein are called a-exophins and those from j-casein
are termed as casoxins. Opioid peptides can be formed
also from whey proteins, that is a-lactorphins from
a-lactalbumin and b-lactorphins from b-lactoglobulin
(Wada et al., 2017). Han et al., 2013 investigated the
effects of b-casomorphine-7 on diabetic cardiomyopa-
thy in a rat model of diabetes. They found that b-caso-
morphine-7 exerted protective effects on the heart and
possessed also antioxidative properties.
Nurminen et al. (2000) administered sucutaneously
a-lactorphin, a four amino acid peptide derived from
a-lactalbumin, to hypertensive and normotensive rats.
The blood pressure was reduced similarly in both
strains and this effect could be abolished by pre-treat-
ment with the opioid receptor (mu, delta and kappa
receptors) antagonist emphasising the role of opioid
receptors in the pressor response. Furthermore, Haya-
shida et al., 2004 investigated the effects of bovine
lactoferrin on blood pressure and vascular function in
normotensive rats; they reported that an intravenous
injection of lactoferrin dose-dependently lowered blood
pressure. Once again, the hypotensive effect was
blocked by pre-treatment with naloxone. The authors
concluded that lactoferrin’s hypotensive effect could
partly be regulated via opioid receptors, although vas-
cular relaxation was dependent on nitric oxide release
from the endothelium.
Other milk components with possible blood
pressure lowering activity
In addition to bioactive peptides, dairy products con-
tain many other factors which, at least theoretically,
can lower blood pressure and/or improve vascular dys-
function (see Chrysant & Chrysant, 2013).
The electrolytes present in dairy products, most
notably calcium, potassium and magnesium lower the
systolic blood pressure by 1.3–4.6 mmHg and diastolic
blood pressure by 0.2–3.8 mmHg in long-term human
interventions (see, Kris-Etherton et al., 2009) and
higher dietary calcium intake is slighty associated with
lower risk of developing hypertension (Jayedi & Zar-
gar, 2018). McGarron was one the pioneers who stud-
ied the relationship of calcium and blood pressure; he
identified low serum concentrations of ionised calcium
in patients with hypertension (see McGarron, 1982).
The calcium effect was complex, because a low calcium
intake increased the intracellular calcium concentration
as well as elevated vitamin D3 and parathyroid hor-
mone concentrations. These changes induced calcium
influx into vascular smooth muscle cells and further
increased the vascular tone. Acute and chronic effects
of calcium are different. Sodium status and possibly
even the calcium salt used in the dietary experiments
can influence the findings. The role of adrenergic stim-
ulation due to acute hypercalcaemia has been demon-
strated both in normotensive and even more clearly in
borderline hypertensive subjects (Bianchetti et al.,
1983). Since the calcium concentration in milk is mod-
est (approx. 120 mg per 100 mL), it is not anticipated
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that the acute blood pressure or vascular effects would
be influenced by drinking milk. In epidemiological
studies, exact data on the consumption of daily milk
and other dairy products are, at best, approximations
and most often not correlated with other vasoactive
components present in the diet. It seems that it is the
balance between sodium and calcium intake which is
important. Increased natriuresis has been proposed as
a mechanism by which calcium intake may reduce
blood pressure (Lasaridis et al., 1989) since this would
be accompanied by a reduction in total body water
content (Zemel et al., 1988), in contrast to the acute
effects of calcium. These observations were supported
by experimental findings reported by M€akynen (1996)
showing that the blood pressure of hypertensive rats
on a high calcium diet (2.5%) lowered in a 10–12-
week-long intervention but a magnesium enriched
diet alone or in combination with calcium exerted no
additive blood pressure lowering effect. In contrast, a
dietary potassium and magnesium enriched salt alter-
native improved further the beneficial cardiovascular
effects of an ACE-inhibitor in hypertensive rats (Mer-
vaala et al., 1994). A recent review concludes, based
on studies on low (Kostov and Halacheva, 2018) and
high magnesium intake, that magnesium supplementa-
tion has blood pressure lowering effect (Schutten et al.,
2018). However, the contents of magnesium (approx.
11 mg per 100 mL) and potassium (approx. 150 mg
per 100 mL) in milk are so low that it is unlikely that
their concentrations in plasma and tissue would be
influenced by dietary intake in individuals with normal
kidney function.
A low level of vitamin D in plasma has been postu-
lated to be associated with elevated blood pressure
and further cardiovascular events. In an extensive sys-
tematic review and meta-analysis (Beveridge et al.,
2015), it was concluded that vitamin D supplementa-
tion, even at much higher doses than present in milk
(1 lg per 100 mL without enrichment), was ineffective
as a blood pressure lowering component and should
not be considered as hypertension treatment, but it is
not known whether it could act synergistically with
dairy calcium.
L-arginine is a precursor for the physiological
vasodilator nitric oxide (NO) in endothelium. The
arginine content in milk is about 100 mg per 100 mL
and in cheddar cheese about 250 mg per 100 g. There-
fore, milk arginine cannot on its own be a potential
blood pressure lowering factor, because in clinical tri-
als when intravenously administered L-arginine was
administered as a single dose of either 6 or 30 g, only
the higher dose lowered blood pressure and reduced
total peripheral resistance in healthy humans (Bode-
B€oger et al., 1998). Alba et al. (2016) hypothesised
that acute dairy milk consumption increases endothe-
lial nitric oxide (NO) in testing the cutaneous
vasodilatation in healthy volunteers, but could not
show that ingestion of milk would augment NO-
dependent vasodilatation in the cutaneous microcircu-
lation.
It can be summarised that with respect to the known
vasoactive components of milk, only calcium – in
addition to the bioactive peptides – seems to con-
tribute to the beneficial effects of milk on blood pres-
sure and arterial function.
Conclusions
Milk contains a great number of proteins which either
during food processing or in the gastrointestinal tract
can be degraded into peptides that possess antihyper-
tensive effects. Epidemiological studies have revealed
that a high intake of low-fat dairy products and/or fer-
mented dairy products is associated with reduced
blood pressure. Although there are several possible
mechanisms by which dairy products can lower blood
pressure, ACE inhibition by the bioactive peptides has
been the most extensively studied mechanism. These
peptides and calcium are the most important blood
pressure lowering milk components. The antithrom-
botic and opioid-like effects of the peptides may be
involved but more clinical studies are needed to con-
firm these findings.
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